MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer

Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli

ABSTRACT

Background Endogenous retroviruses (ERVs) are highly expressed in various cancer types and are associated with increased innate immune response and better efficacy of antiprogrammed death-1/ligand-1 (anti-PD1/PD-L1)-directed immune checkpoint inhibitors (ICI) in preclinical models. However, their role in human non-small cell lung cancer (NSCLC) remains unknown.

Methods We conducted a retrospective study of patients receiving ICI for advanced NSCLC in two independent cohorts. ERV expression was determined by RNA sequencing. The primary endpoint was progression-free survival (PFS) under ICI. The secondary endpoint was overall survival (OS) from ICI initiation. We studied expression of 6205 ERVs. Multivariate Cox regression model with lasso penalty was estimated on the training set to select ERVs significantly associated with survival. The predictive power of these ERVs was compared with that of previously described transcriptomic signatures.

Results We studied two independent cohorts of 89 and 70 patients, used as training and validation sets. Clinicopathological characteristics included 75% of patients with non-squamous NSCLC. We selected four ERVs significantly associated with PFS. Only high MER4 ERV was associated with better PFS and OS in both cohorts. From a biological point of view, high MER4 expression is associated with higher infiltration of eosinophils and inflammatory gene signatures, while low MER4 expression is associated with enrichment in metabolism and proliferation signatures. Adding MER4 to previously described transcriptomic signatures of response to ICI improved their predictive power.

Conclusions MER4 ERV expression is useful to stratify risk and predict PFS and OS in patients treated with ICI for NSCLC. It also improves the predictive power of other known transcriptomic signatures.

INTRODUCTION

Lung cancer is the most common form of cancer globally.1 The majority of lung cancers are classified as non-small cell lung cancer (NSCLC).2 In patients without targetable mutations, the main treatments rely on cytotoxic chemotherapies and checkpoint inhibitors, used either concomitantly or sequentially.3 In this context of tumor without oncogenic addiction, immunotherapy and especially, drugs targeting antiprogrammed death-1/ligand-1 (PD-1/PD-L1) immune checkpoint inhibitors (ICI) have changed the field of thoracic oncology treatment. Initially, patients with advanced NSCLC were treated with chemotherapy followed by anti-PD-1 monoclonal antibodies (mAb). Currently, ICI are becoming standard in the first-line treatment of advanced NSCLC as monotherapy for patients with PD-L1 expression above 50%, and in association with chemotherapy for all-comers with NSCLC.4-6 Despite good efficacy, a majority of patients experience primary or secondary resistance, and availability of efficient predictive biomarkers of response to ICI remain an unmet clinical need. Although a large number of biological studies have tested complex biomarkers, the only approved biomarker remains PD-L1 immunohistochemistry. In addition to PD-L1, various genomics and transcriptomics biomarkers have been developed, such as tumor mutational burden or various transcriptomics signatures.7-9

About 9% of the human genome contains endogenous retrovirus (ERV) sequences.10 Usually, their expression is silenced in most somatic tissues due to epigenetic control. In contrast, reports have suggested that some ERVs are transcribed in various cancer types.11 Expression of ERVs is classically associated with induction of inflammatory responses, and epigenetic modifier drugs were shown to trigger re-expression of ERVs with better efficacy of ICIs in preclinical models.11,12 In renal carcinoma, an association between expression of some ERVs and both tumor immune signatures and ICI efficacy was recently described.13 Taken together, these data raise the hypothesis that abnormal expression of immunogenic ERVs may elicit an antitumor immune response that could render the
tumor more likely to benefit from ICI blockade. However, specific data are lacking for NSCLC.

In this study, we aimed to determine the predictive role of ERV mRNA expression in NSCLC treated with ICI. We also evaluated the ability of ERV analysis to improve the predictive capacity of classical transcriptomics immune signatures.

**MATERIALS AND METHODS**

**Study population**

We disposed of two cohorts of patients with NSCLC receiving treatment with anti-programmed death 1 (PD-1/PD-L1) checkpoint inhibitors between 2014 and 2020. Cohort 1 was composed of 89 patients treated in the Georges François Leclerc Cancer center or the University Hospital of Dijon or the Hospital of Montréal and cohort 2 was composed of 70 patients treated in the Georges François Leclerc Cancer center. For all patients, abundance of transcripts from RNA-seq data was available, sequenced on different platforms using different technology for mRNA isolation (ribosome depletion for cohort 1 and polyA purification for cohort 2).

Only patients from whom informed consent was obtained and recorded in the medical chart were included in this retrospective study.

For RNAseq analysis, this study falls within the scope of the biological collection authorization registered under the number AC-2014–2260.

**PD-L1 expression analysis**

PD-L1 protein expression in tumor cells was assessed using immunohistochemistry with a ready-to-use PDL1 commercial kit with using 22C3 antibodies (22C3 pharmDX; Agilent, Santa Clara, California, USA) or PD-L1 concentrate Ab clone QR1 (Diagomics) or clone SP142 (Ventana). PD-L1 positivity was defined as >1% of cells in tumor. In this study, we just considered PD-L1 as positive or negative, we chose not to consider this variable as continuous.

**LIPI score calculation**

Blood cell counts and lactate dehydrogenase (LDH) levels at baseline before ICI treatment (within 30 days prior to the first treatment) were obtained from the electronic medical records. Demographic, clinical, pathological, and molecular data were also collected.

The LIPI (Lung Immune Prognostic Index) was developed on the basis of the derived neutrophil/lymphocyte ratio (dNLR = leucocytes/(leucocytes – neutrophils)>3) or LDH>230 U/L (considered as the upper limit of normal in our center). We considered two distinct groups: negative if neither of these two conditions was met, and positive if one or both conditions were met.

**RNAseq data**

For cohort 1, total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor slices (5×5 μm) using the Maxwell 16 LEV RNA FFPE Purification kit (Promega) following the manufacturer’s instructions. Libraries were prepared from 12 μL of total RNA with the TruSeq Stranded Total RNA using Ribo-Zero (Illumina) following the manufacturer’s instructions. Once qualified, paired-end libraries were sequenced using 2×75 bp output on a NextSeq 500 device (Illumina).

For cohort 2, 10 ng of total RNA or 40 ng from FFPE were fragmented and 3’-end of mRNA were captured using an RT primer poly(T) containing a unique molecular identifier. Illumina adapters were added during this step by template switching. Fragments were then amplified with two PCR to complete Illumina adapters and add index sequencing. Libraries were sequenced on NovaSeq 6000 platform.

Abundance of transcripts was quantified using the Kallisto program. This program is based on pseudo-alignment for rapidly determining the compatibility of reads with targets, without the need for alignment. The Kallisto transcript index used as reference was built from merged human cDNA and ncDNA files from the GRCh37 assembly ENSEMBL. Gene-level count matrices were then created with the DESeq2 library. Low-count genes were prefiltered by removing genes with too few reads.

Genes differentially expressed according to MER4 expression were selected using the DESeq2 R package. cohorts were pooled and batch effect was accounted for by adding cohort as a covariate in the regression model. Gene set enrichment analysis (GSEA) was performed on resulting differential genes using Hallmarks of cancer gene sets from the Broad Institute and the R package ‘clusterProfiler’.

**Detection of ERVs**

ERV sequences were detected using Telescope software. Only ERV sequences detected with more than five reads in more than two patients were considered. With this filtering, 6205 ERVs common to both cohorts were retained for analysis.

**Immune cell signatures**

The abundance of 10 tissue-infiltrating immune and stromal cell populations (CD3+ T cells, CD8+ T cells, cytotoxic lymphocytes, NK (Natural Killer) cells, B lymphocytes, mononuclear lineage, myeloid dendritic cells (DCs), neutrophils, endothelial cells, and fibroblasts) were estimated using transcriptomic profiles and the microenvironment cell population-counter (MCP-counter) method. This analysis was performed on variance-stabilized RNAseq data. Batch effect due to different platforms was removed using removeBatchEffect() function from the limma R package.

Twenty-eight immune subpopulations were evaluated using single-sample gene set enrichment analysis (ssGSEA) based on gene signatures following the methodology proposed by Charoentong et al. including major types related to adaptive immunity: activated T cells, central memory (Tcm), effector memory (Tem) CD4+ T cells, and activated B cells. After enrichment, expression levels of CD3, CD8, and CD4 were averaged for each patient to create a score representing cell abundance. This score was transformed to a log scale to be used as a continuous variable in the regression model.
and CD8+T cells, gamma delta T (Tgd) cells, T helper 1 (Th1) cells, Th2 cells, Th17 cells, regulatory T cells (Treg), follicular helper T cells (Tfh), activated, immature, and memory B cells, as well as cell types related to innate immunity, such as macrophages, monocytes, mast cells, eosinophils, neutrophils, activated, plasmacytoid, and immature DCs. ssGSEA analysis was performed on log2(TPM+1) as advised. To take into account the platform effect, z-scores were computed on log2(TPM+1) and batch effect was removed on this transformed data using the ComBat function from sva R package.

Transcriptomic signatures

Six transcriptomic signatures were computed as a metagene by taking the mean expression of corresponding genes. Expression was based on variance-stabilized RNAseq data and batch effect due to different platforms was removed as described above. Three signatures are related to IFN pathways or checkpoint inhibitors: IFNγ, extended immune gene signature (EIG), and T cell-inflamed gene expression profile (GEP) and four are related to T cell immune infiltrate: cytotoxicity (CYTOX), TH1 orientation (TH1), cytotoxic lymphocytes (CTL), and CD274 gene expression (online supplemental table 1).23 24

Statistical analysis

Patient characteristics were compared by group of origin (cohort 1 or cohort 2) using the χ² or Fisher’s exact test for qualitative variables, and the Wilcoxon test for continuous variables, as appropriate. P values were adjusted using Benjamini-Hochberg FDR correction and adjusted p<0.05 were considered significant.

Progression-free-survival (PFS) was calculated from the date of first immunotherapy administration until disease progression or death from any cause, and was evaluated at 6 months. Patients who were alive with no progression at 6 months were censored. Overall survival (OS) was calculated from the date of first immunotherapy administration until death from any cause and was censored at 1 year.

Survival analysis was performed using the survival R library. The prognostic value of the different variables was tested using univariate or adjusted multivariate Cox regression with lasso penalty for PFS and OS. Survival probabilities were estimated using the Kaplan-Meier method and survival curves were compared using the log-rank test. P values less than or equal to 0.05 were considered statistically significant. Nested models were compared using the likelihood ratio test (LRT) and the area under the curve (AUC).

Statistical analyses were performed using the R software (http://www.R-project.org/) and graphs were drawn using GraphPad Prism V9.0.2.

RESULTS

Patient characteristics

In total, 159 patients treated with ICI (in first or further lines) for metastatic NSCLC were retained for analysis in two independent cohorts sequenced on two different platforms. Median age was 66 years (IQR=14), and 75% of patients had non-squamous NSCLC. One hundred and forty-one patients (89%) received anti-PD-1 therapies (nivolumab or pembrolizumab) while the others received atezolizumab or durvalumab. PD-L1 status was available for 73 patients (46%), and PD-L1 expression was detected as positive in 57 of these patients (78%). Clinical characteristics did not differ between both cohorts. The main characteristics of the population are reported in online supplemental table 2.

Association between ERVs and ICI efficacy

Median number of ERVs was 764 (IQR=76) for cohort 1 and 115 (IQR=130) for cohort 2. Median ERV overall expression (total number of reads detected for each patient) was 4634 (IQR=484) in cohort 1 and 940 (IQR=780) in cohort 2. Neither total number of ERVs detected per patient nor overall ERV expression was associated with progression-free survival (PFS), or with OS (online supplemental table 3).

To investigate further, we searched for ERVs whose expression was associated with PFS using cohort 1 as a training set and cohort 2 as a validation set. A first selection was performed using univariate Cox models in cohort 1 on 6205 ERVs common to both cohorts; 464 ERVs were found to be associated with PFS. After selection by multivariate Cox regression with lasso penalty, four selected ERVs (MER4 6p22-3c, LTR19 9q34-11, HERVFDR 3p21-31, and ERVLE 4q33-a) were found to be associated with PFS in cohort 1 by univariate analysis (table 1). Using cohort 2 as a validation set, we found that only high expression of MER4 6p22-3c ERV remained associated with better PFS by univariate analysis (table 1). Using the third quartile of this ERV’s expression in cohort 1 as a cut-off we observed that high MER4 6p22-3c ERV expression was associated with better PFS in both cohorts (HR=0.3 (0.2 to 0.7), p=0.006 in cohort 1 and HR=0.4 (0.2 to 0.9), p=0.02 in cohort 2) (figure 1A,B). Moreover, high MER4 6p22-3c ERV expression was associated with better OS in both cohorts (HR=0.6 (0.2 to 1.3), p=0.16 and HR=0.3 (0.1 to 1), p=0.04, respectively, for cohorts 1 and 2) (figure 1C,D).

Next, we evaluated whether MER4 6p22-3c was an independent prognostic marker independently of clinical variables. In the following analyses, MER4 expression was dichotomized based on third quartile expression in cohort 1 and patients were considered as MER4low or MER4High, according to whether they were, respectively, below or above the third quartile. As both cohorts had comparable clinical characteristics, they were pooled for this analysis (table 2). We observed that high MER4 6p22-3c ERV expression was associated with better PFS (as continuous variable: HR=0.8 (0.7 to 0.9), p=1×10⁻³, as binary variable: HR=0.3 (0.2 to 0.6), p=1×10⁻³) and OS (as continuous variable: HR=0.8 (0.7 to 0.9), p=1×10⁻³, as binary variable: HR=0.4 (0.2 to 0.8), p=0.01). Similarly, MER4 6p22-3c ERV expression taken as a continuous
variable is associated with disease control rate ($p=0.01$). Poor performance status and use of ICI after the first line were not associated with poorer PFS, while only poor performance status was associated with poorer OS (HR=2.9 (1.3 to 6.2), $p=0.007$). Only the presence of bone metastasis (HR=2.1 (1.2 to 3.5), $p=0.006$), a high dNLR score (HR=1.2 (1 to 1.5), $p=0.01$) and a LIPI score greater than one (HR=2.2 (1.2 to 1.5), $p=0.008$) were associated with poorer PFS. These variables were also associated with poorer OS (Table 2). Using a multivariate Cox model including LIPI score, bone metastasis, and MER4 expression, all three variables remained significantly associated with PFS, with HR=2.5 (1.4 to 4.4) ($p=0.001$) for presence of bone metastasis, HR=2.3 (1.5 to 4.1) ($p=0.005$) for LIPI score and HR=0.35 (0.13 to 0.99) ($p=0.05$) for MER4High expression.

Clinical characteristics were compared between MER4High and MER4Low patients. No significant difference was observed (online supplemental table 4).

We next evaluated the incremental predictive capacity of MER4 expression relative to PD-L1 status, as this latter marker is classically used as an anti PD-1/anti PD-L1 mAb

![Figure 1](https://jitc.bmj.com/)

**Figure 1** Association between survival and MER4 6p22.3c ERV expression. Kaplan-Meier curves with patients stratified according to MER4 6p22.3c ERV expression (low vs high) for progression-free survival (A) in cohort 1, (B) in cohort 2 and for overall survival (C) in cohort 1 and (D) in cohort 2. ERV, endogenous retrovirus.

| ERV     | Cohort 1          | Cohort 2          |
|---------|-------------------|-------------------|
| PFS     |                   |                   |
| MER4 6p22.3c | HR=0.6 (0.5 to 0.7), $p<1 \times 10^{-3}$ | HR=0.8 (0.7 to 0.9), $p=0.005$ |
| LTR19 9q34.11 | HR=1.4 (1.2 to 1.7), $p<1 \times 10^{-3}$ | HR=1 (0 to 1), $p=0.92$ |
| HERVFRD 3p21.31 | HR=0.6 (0.4 to 0.8), $p=0.001$ | HR=0.8 (0.6 to 1), $p=0.1$ |
| ERVE 4q33a | HR=0.6 (0.4 to 0.8), $p=0.001$ | HR=0.4 (0.1 to 1.9), $p=0.26$ |
| OS      |                   |                   |
| MER4 6p22.3c | HR=0.7 (0.5 to 0.9), $p=0.003$ | HR=0.8 (0.71 to 0.95), $p=0.01$ |
| LTR19 9q34.11 | HR=1.5 (1.2 to 1.8), $p<1 \times 10^{-3}$ | HR=0.9 (0.6 to 1.3), $p=0.53$ |
| HERVFRD 3p21.31 | HR=0.7 (0.5 to 0.94), $p=0.02$ | HR=0.8 (0.6 to 1.1), $p=0.17$ |
| ERVE 4q33a | HR=0.6 (0.4 to 0.9), $p=0.01$ | HR=0.5 (0.1 to 2.3), $p=0.41$ |

Table 1: Univariate Cox model for PFS and OS in cohorts 1 and 2 for ERVs selected by multivariate Cox regression model with lasso penalty

Univariate Cox model was described by the HR, the CI at 95% and the p value.

ERV, endogenous retrovirus; OS, overall survival; PFS, progression-free survival.
Table 2  Univariate and multivariate Cox models for PFS and OS including clinical variables in pooled cohorts 1 and 2

| Variables                  | PFS       | OS         |       |       |
|----------------------------|-----------|------------|-------|-------|
|                            | Univariate| Multivariate| Univariate| Multivariate|
| Sex                        |           |            |       |       |
| Male                       | 1         | 1          | 1     | 1     |
| Female                     | HR=0.7 (0.5 to 1.1), p=0.12 |           | HR=0.6 (0.4 to 1), p=0.07 | HR=0.6 (0.2 to 1.3), p=0.21 |
| Age at diagnosis           |           |            |       |       |
| ≤60                        | 1         | 1          | 1     | 1     |
| >60                        | HR=0.9 (0.6 to 1.4), p=0.64 |           | HR=0.8 (0.5 to 1.3), p=0.37 | |
| Smoking status             |           |            |       |       |
| Never smoker               | 1         | 1          | 1     | 1     |
| Current or former smoker   | HR=0.6 (0.3 to 1.5), p=0.32 |           | HR=0.6 (0.2 to 1.8), p=0.42 | |
| Histological type          |           |            |       |       |
| Adenocarcinoma             | 1         | 1          | 1     | 1     |
| Other                      | HR=1 (0.6 to 1.5), p=0.89 |           | HR=1 (0.6 to 1.6), p=0.9 | |
| WHO performance status     |           |            |       |       |
| 0                          | 1         | 1          | 1     | 1     |
| >0                         | HR=1.2 (0.7 to 2.1), p=0.42 |           | HR=2.9 (1.3 to 6.2), p=0.007 | HR=1.6 (0.6 to 4.2), p=0.3 |
| Cerebral metastasis        |           |            |       |       |
| No                         | 1         | 1          | 1     | 1     |
| Yes                        | HR=1.4 (0.8 to 2.4), p=0.25 |           | HR=1.1 (0.6 to 2.2), p=0.7 | |
| Liver metastasis           |           |            |       |       |
| No                         | 1         | 1          | 1     | 1     |
| Yes                        | HR=1.2 (0.7 to 2), p=0.56 |           | HR=1.1 (0.6 to 2.1), p=0.7 | |
| Bone metastasis            |           |            |       |       |
| No                         | 1         | 1          | 1     | 1     |
| Yes                        | HR=2.1 (1.2 to 3.5), p=0.006 | HR=2.8 (1.5 to 5.1), p=0.001 | HR=2.7 (1.4 to 5.3), p=0.002 | HR=3.7 (1.6 to 8.5), p=0.002 |
| Lymph node metastasis      |           |            |       |       |
| No                         | 1         | 1          | 1     | 1     |
| Yes                        | HR=0.6 (0.3 to 1.2), p=0.13 |           | HR=0.8 (0.3 to 1.8), p=0.56 | |
| Pleuropertitoneal metastasis|           |            |       |       |
| No                         | 1         | 1          | 1     | 1     |
| Yes                        | HR=1.4 (0.8 to 2.5), p=0.21 |           | HR=1.3 (0.7 to 2.4), p=0.46 | |
| Line of ICI                |           |            |       |       |
| 1                          | 1         | 1          | 1     | 1     |
| >1                         | HR=0.9 (0.6 to 1.3), p=0.53 |           | HR=1.4 (0.8 to 2.4), p=0.2 | |
| Type of ICI                |           |            |       |       |
| Anti-PD-1                  | 1         | 1          | 1     | 1     |
| Anti-PD-L1                 | HR=1.3 (0.5 to 3), p=0.63 |           | HR=1.4 (0.5 to 3.8), p=0.51 | |
| Anti-PD-L1+anti-CTLA4      | HR=1.2 (0.5 to 3), p=0.68 |           | HR=0.75 (0.2 to 2.4), p=0.62 | |
| Anti-PD-1+anti-CTLA4       | HR=0.86 (0.21 to 3.5), p=0.83 |           | HR=0.6 (0.1 to 4.6), p=0.66 | |
| Other association          | HR=3.6 (0.5 to 26), p=0.21 |           | – | |
| PD-L1 status (cut-off at 1%)|           |            |       |       |
| Negative tumors            | 1         | 1          | 1     | 1     |
| Positive tumors            | HR=0.6 (0.3 to 1.1), p=0.13 |           | HR=0.7 (0.3 to 1.4), p=0.27 | |
| LDH                        | HR=1 (1 to 1), p=0.12 |           | HR=1 (1 to 1), p=0.01 | |
| dNLR                       | HR=1.2 (1 to 1.5), p=0.01 |           | HR=1.5 (1.2 to 1.8), p<1x10^{-3} | |
| LIPI score                 |           |            |       |       |

Continued
biodmarker in clinical practice. As PD-L1 status based on immunohistochemistry staining was missing for a large proportion of patients, PD-L1 status was inferred from CD274 gene expression based on RNA sequencing. Using the first quartile of CD274 expression as a cut-off we observed that high expression of this gene was associated with better PFS (HR=0.5 (0.3 to 0.8), p=0.002) (figure 2A) and better OS (HR=0.4 (0.3 to 0.9), p=0.02) (online supplemental figure 1A). Also weak, correlation between CD274 and MER4 expression was significant (Pearson coefficient=0.2; p=0.01). A multivariate model including CD274 mRNA expression level and MER4 6p22-3c expression (dichotomized according to the third quartile expression in cohort 1) was also estimated. MER4 status had an incremental predictive value compared with PD-L1 information alone in terms of PFS (AUC=0.7 vs 0.6, LRT p<1×10⁻³) and OS (AUC=0.64 vs 0.57, LRT p=0.002) (figure 2B and online supplemental figure 1B). To explore further, we compared immune infiltration between MER4High and MER4Low patients. Based on MCP-counter analysis, no significant difference was observed (figure 3C). Using immunophenoscore signatures as

### Table 2

Continued

| Variables | PFS Univariate | PFS Multivariate | OS Univariate | OS Multivariate |
|-----------|----------------|-----------------|---------------|-----------------|
|           |                |                 |               |                 |
| 0         | 1              | 1               | 1             | 1               |
| >0        | HR=2.2 (1.2 to 3.8), p=0.008 | HR=2.4 (1.3 to 4.5), p=0.003 | HR=3 (1.5 to 6.1), p=0.002 | HR=2.8 (1.3 to 6), p=0.006 |
| EGFR      |                |                 |               |                 |
| WT        | 1              | 1               | 1             | 1               |
| Mutated   | HR=0.65 (0.2 to 2.7), p=0.55 | HR=0.4 (0.05 to 2.8), p=0.34 | HR=1.2 (0.7 to 2.1), p=0.51 | HR=2 (1.1 to 3.7), p=0.03 |
| KRAS      |                |                 |               |                 |
| WT        | 1              | 1               | 1             | 1               |
| Mutated   | HR=1.3 (0.3 to 5.5), p=0.72 | HR=1.6 (0.4 to 6.6), p=0.54 | HR=0.3 (0.2 to 0.6), p<1×10⁻³ | HR=0.4 (0.1 to 1.1), p=0.06 |
| BRAF      |                |                 |               |                 |
| WT        | 1              | 1               | 1             | 1               |
| Mutated   | HR=12.3 (2.6 to 58), p=0.001 | HR=19.6 (3.6 to 107), p<1×10⁻³ | HR=1.3 (0.2 to 9.7), p=0.78 | HR=0.4 (0.2 to 0.8), p=0.01 |
| MET       |                |                 |               |                 |
| WT        | 1              | 1               | 1             | 1               |
| Mutated   | HR=1.3 (0.3 to 5.5), p=0.72 | HR=1.6 (0.4 to 6.6), p=0.54 | HR=0.3 (0.2 to 0.6), p<1×10⁻³ | HR=0.4 (0.1 to 1.3), p=0.11 |
| MER4      |                |                 |               |                 |
| Low       | 1              | 1               | 1             | 1               |
| High      | HR=0.3 (0.2 to 0.6), p<1×10⁻³ | HR=0.4 (0.1 to 1.1), p=0.06 | HR=0.4 (0.2 to 0.8), p=0.01 | HR=0.4 (0.1 to 1.3), p=0.11 |

Multivariate Cox models were constructed using variables significantly associated with survival by univariate Cox models (with a p<0.1). As the LIPI score was selected, LDH and dNLR were not included because these variables are used to compute the LIPI score.

ICI, immune checkpoint inhibitors; LIPI, Lung Immune Prognostic Index; OS, overall survival; PD-1, programmed death-1; PFS, progression-free survival.
reported by Charoentong et al., we observed accumulation of mast cells (adjusted p=0.04), eosinophils (adjusted p=0.04), regulatory T cells (adjusted p=0.04), and T follicular helper cells (adjusted p=0.04) in MER4High patients (figure 3D), thus suggesting better immune reactivity in such tumors.

Together, these results underline that MER4 expression was associated with an inflammatory phenotype and accumulation of innate and adaptive T cells.

**MER4 adds predictive power to transcriptomic signatures**

Previous studies have underlined that transcriptomic signatures related to IFN pathways or checkpoint inhibitors could be used to predict the efficacy of checkpoint inhibitors in various cancer types. Accordingly, we tested in our series the predictive role of IFN-γ, extended immune gene signature (EIG), and T cell-inflamed gene expression profile (GEP) (online supplemental table 1). Each signature, considered as a continuous variable, was significantly associated with better PFS by univariate Cox analysis, yielding AUCs between 0.62 and 0.65 (online supplemental table 5 and online supplemental figure 2A). We also used the signature of T cell accumulation in the tumor, which we previously showed to be associated with better response to ICI. Accordingly, we computed gene signatures, respectively, associated with Th1 response, cytotoxic response, and presence of CD8 T cells (online supplemental table 1). Each signature was significantly associated with better PFS by univariate Cox analysis, yielding AUCs between 0.62 and 0.67 (online supplemental table 5). Similar results were observed for OS (online supplemental table 5 and online supplemental figure 2B).

To test the capacity of the ERV model to improve prognostic prediction, we generated models that combined MER4 expression with each previously described signature. Comparison of the models using the LRT showed that MER4 improved the predictive power of all gene signatures (online supplemental table 5 and online supplemental figure 2C).
supplemental figure 2A). Similar results were observed for OS (online supplemental table 5 and online supplemental figure 2B).

Using the best statistical model for PFS, which included CTL signature and MER4 expression, we separated patients into four groups using the median as the cutoff for the CTL signature. High expression of MER4 6p22.3c was associated with improved PFS. Patients classified as CTLLow/MER4High had a significantly better PFS than patients CTTL/MER4Low (median follow-up not reached vs 1.8 (1.6;2.6) months, HR=0.2 (0.1 to 0.5), p=1x10^-3), while CTLHigh/MER4High patients seemed to have a better PFS than CTTL/MER4Low patients (median follow-up not reached 4.3 vs not reached) months, HR=0.5 (0.2 to 1.1), p=0.09) (online supplemental figure 2C). Similar results were observed for OS. Patients classified CTLLow/MER4High had better OS than CTLLow/MER4Low patients (median follow-up not reached vs 5.9 (3.9;10.2) months, HR=0.1 (0.03 to 0.6), p=0.007) (online supplemental figure 2D).

**DISCUSSION**

This study provides novel insights into the role of MER4 ERV in predicting response to anti PD-1 therapy in NSCLC treated with anti PD-1/PD-L1.

Classically, it is thought that the accumulation of all ERVs could trigger inflammatory response. This article underlines that the type of ERVs might be more important than the global number of ERVs. Such data suggest the hypothesis that viral mimicry triggered by specific ERVs could promote immune response to ICIs.

Human ERVs derive from ancestral exogenous retroviruses, whose genetic material is integrated in human germline DNA. ERV sequences in humans account for about 9% of the genome.25 Human ERVs are grouped into three classes, from I to III, based on similarity with the exogenous Gammaretrovirus, Betaretrovirus, and...
Syncytin mediation of cell fusion can also promote cell fusion in cancer cells, a process known to be related to cancer progression, metastasis, and chemoresistance. In our study, using GSEA analysis, we report that MER4 ERV expression is inversely associated with upregulation of Myc and E2F target genes, which are classically known to be related to the epithelial-mesenchymal transition process. Similarly, higher expression of glycolysis, mTORC1, DNA repair, and G2M checkpoint pathway in MER4low tumor indicates more proliferative tumors. Our results raise the hypothesis that MER4 could negatively regulate the epithelial-mesenchymal transition process and tumor cell proliferation.

ERVs could also have a major role in immune response. First, ERV proteins could code for tumor associated neoantigens. Second, their mRNA is able to impact on both innate and adaptive immune responses via various mechanisms. The mRNA of ERVs could be detected by RIG-I-like and TLR3. RIG-I receptors mediate activation of the adaptor molecule called mitochondrial antiviral signaling protein, thus leading to activation of type I IFN signaling pathway via the activation of IFN regulatory factors 3 (IRF3), and induce nuclear factor κB (NF-κB) activation. TLR3 induces activation of Type I IFN and CXCL9/CXCL10 production via the activation of IRF1. In addition Type I IFN promotes cancer cell immunogenicity by inducing the expression of class I MHC on tumor cells, thus enhancing T cell adaptive immune response. In contrast, some reports underline that ERVs could harbor immunosuppressive functions. For example, ERVs could decrease production of IL-2 and CXCL9 by immune cells. ERVs contain a sequence called immunosuppressive domain, which could modulate the activation of immune cells. Syncytins are known to protect the fetus from the mother’s immune system and ERVs can use this system to help cancer to fight against the host immune system. In our study, not the overall number or expression of ERVs is associated with outcome but rather only MER4 expression. This suggests that some ERVs may have both positive and negative effects on cancer growth and immune response. While we observed a greater signature of inflammatory immune response, and high accumulation of both adaptive and innate immune cells in the MER4high group, these data suggest a positive immune effect of this particular ERV. In metastatic renal cell carcinoma, ERV-4 HERV expression was associated with increased disease control rate and longer PFS in nivolumab treated patients but not in everolimus treated patients. The latter generalizes the role of HERV in cancer treated with immunotherapy and support a prediction rather than a prognostic role.

Combination of epigenetic drug plus ICIs is an emerging field and shows promising results in clinical trials. Recent studies have identified chromatin regulators with cell-intrinsic effects on the immune sensitivity of cancer cells, raising the possibility that epigenetic therapies could enhance efficacy of ICIs. Double-stranded RNAs can accumulate in cancer cells on derepression of ERVs by epigenetic drugs such as DNA demethylating agents and lysine demethylase 1. It has also been shown that H3K9 methyltransferase SETDB1 derepress retroviral sequences and are control response to ICIs. Such data support the rational that epigenetic drug could influence immune response by targeting ERVs.

MER4 is a member of the ‘HEPSI’ supergroup, which are related to Class I (Epsilonretroviruses, Gammaretroviruses). However, MER4 classification remains complex because these proviruses are highly defective and often do not yield a Pol protein. Very few data are available on the biological role of this virus and our report suggests that it might be important in tuming the antitumor immune response in NSCLC. Interestingly MERK4 is not correlated with other classical predictive factors, thus suggesting that it is a new independent predictive factor.

This study has some limitations, related to its retrospective design and the small number of patients. However, the analysis of two independent series with different technologies gives strength to our observations. Our study involved patients treated in second or further lines with anti-PD-1/PD-L1. Currently, these drugs are used in first line alone or with chemotherapy, so further data on this type of patient are required. Because we could not test patients not treated with immunotherapy, we could not determine the predictive versus prognostic role of this signature. Finally, additional mechanistic demonstrations are required using genetic invalidation of MER4 in human NSCLC cell lines to better explain the mechanism of action of this ERV in NSCLC biology.

To conclude, our study provides novel insights into the role of MER4 as a predictive marker of response to checkpoint inhibitors in NSCLC. It provides evidence that the addition of MER4 to immune transcriptomic signatures could be used to improve prediction.
Author affiliations
1 Platform of Transfer in Biological Oncology, Georges-François Leclerc Cancer Center - UNICANCER, Dijon, Bourgogne-Franche-Comté, France
2 UMR INSERM 1231, Dijon, Bourgogne-Franche-Comté, France
3 Genomic and Immunotherapy Medical Institute, Dijon University Hospital, Dijon, Bourgogne-Franche-Comté, France
4 University of Burgundy-Franche-Comté, Dijon, Bourgogne-Franche-Comté, France
5 Department of Medical Oncology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, Bourgogne-Franche-Comté, France
6 Department of Biopathology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, Bourgogne-Franche-Comté, France
7 Department of Pathology, Quebec Heart and Lung Institute Research Center, Quebec City, Quebec, Canada
8 Department of Medicine Montréal, Division of Oncology, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada
9 University of Montréal, Division of Hematology-Oncology, Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada

Twitter Romain Boidot @boidot_roman

Acknowledgements
The authors would like to thank Integragen (Genepole Campus 1, Erny) for the generation of sequencing data, and Laurence Zitvogel (Institut Gustave Roussy, Paris) for her contribution to the analysis of these data. The authors would also like to thank Dr Fiona Eacott (EA3920, University of Franche-Comté, Besançon) for English correction and helpful comments.

Contributors
Conceptualization: CT, FG. Methodology: JL, CT, Validation: CT, FG. Formal analysis: JL. Data acquisition: JL, CT, LF, CF, AL, CK, RB, SC, PJ, BR. Writing-original draft preparation: JL, CT, FG. Visualization: JL, CT, FG. Supervision: CT, FG. All authors have read and agreed to the published version of the manuscript. Guarantor: FG.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
None declared.

Patient consent for publication
Not applicable.

Ethics approval
The study was conducted according to the guidelines of the Declaration of Helsinki and international legislation and approved by the CNIL (French national commission for data privacy) and the Georges François Leclerc Cancer Center (Dijon, France) local ethics committee (13/085). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Julie Lecuelle http://orcid.org/0000-0003-3181-9126
Caroline Truntzer http://orcid.org/0000-0003-0895-4813
Francois Ghiringhelli http://orcid.org/0000-0002-5465-8305

REFERENCES
1 15-Lung-fact-sheet.pdf, 2020. Available: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
2 Types of lung cancer | LUNGevity Foundation. Available: https://www.lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer
3 Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018;29:v192–237.
4 Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–28.
5 Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.
6 Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92.
7 Cristescu R, Krämer R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018;362:eaar593.
8 Fumet J-D, Truntzer C, Yarchoan M, et al. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer 2020;131:40–50.
9 Ayers M, Lunecford J, Nebozyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017;127:2930–40.
10 Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
11 Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48–61.
12 Jones PA, Ohtani H, Chakravarty A, et al. Epigenetic therapy in immune-oncology. Nat Rev Cancer 2019;19:151–61.
13 Panda A, de Cubas AA, Stein M, et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 2018;3:121522.
14 Ferrucci PF, Ascietto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 2016;27:732–8.
15 Bray NL, Pimentel H, Melsted P, et al. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 2016;34:525–7.
16 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol 2014;15:550.
17 Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomic-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–50.
18 Yu G, Wang L-G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012;16:284–7.
19 Bendall ML, de Mulder M, Iñiguez LP, et al. Telescope: characterization of the retrotranscriptome by accurate estimation of transposable element expression. PLoS Comput Biol 2019;15:e1006453.
20 Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016;17:218.
21 Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 2013;14:7.
22 Charoentong P, Finotello F, Angelova M, et al. Pan-cancer Immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017;18:25–39.
23 Fumet J-D, Richard C, Ladys F, et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer 2018;119:950–60.
24 Ballot E, Ladoire S, Routy B, et al. Tumor infiltrating lymphocytes signature as a new pan-cancer predictive biomarker of anti PD-1/ PD-L1 efficacy. Cancers 2020;12:E6418.
25 Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol 2001;2:REVIEW1017.
26 Ewing AD, Smits N, Sanchez-Luque FJ, et al. Nanopore sequencing enables comprehensive transposable element epigenomic profiling. Mol Cell 2020;80:915–28.
27 Schauer SN, Carreira PE, Shukla R, et al. L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis. Genome Res 2018;28:639–53.
28 Scott EC, Gardner EJ, Masood A, et al. A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer. Genome Res 2016;26:745–55.
López-Moyado IF, Tsagaratou A, Yuita H, et al. Paradoxical association of T cell loss with function with genome-wide DNA hypomethylation. *Proc Natl Acad Sci U S A* 2019;116:16933–42.

Ardeljan D, Steranksa JP, Liu C, et al. Cell fitness screens reveal a conflict between LINE-1 retrotransposition and DNA replication. *Nat Struct Mol Biol* 2020;27:168–78.

Doucet-O’Hare TT, Rodić N, Sharma R, et al. Line-1 expression and retrotransposition in Barrett’s eosophagus and esophageal carcinoma. *Proc Natl Acad Sci U S A* 2015;112:E4894–900.

Babaian A, Romanish MT, Gagnier L, et al. Onco-exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma. *Oncogene* 2016;35:2524–6.

Lemaitre C, Tsang J, Bireau C, et al. A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion. *PLoS Pathog* 2017;13:e1006451.

Bjerregaard B, Holck S, Christensen IJ, et al. Syncytin is involved in breast cancer-endothelial cell fusions. *Cell Mol Life Sci* 2006;63:1906–11.

Strick R, Ackermann S, Langbein M, et al. Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral syncytin-1 and regulated by TGF-beta. *J Mol Med* 2007;85:23–38.

Kellner D, Rinn J. Transposable elements reveal a stem cell-specific class of long non-coding RNAs. *Genome Biol* 2012;13:R107.

Kannan S, Chernikova D, Rogozin IB, et al. Transposable element insertions in long intergenic non-coding RNA genes. *Front Bioeng Biotechnol* 2015;3:71.

Wang J, Xie G, Singh M, et al. Primate-specific endogenous retrovirus-driven transcription defines naive-like stem cells. *Nature* 2014;516:405–9.

Yin S, Cheryan VT, Xu L, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. *PloS One* 2017;12:e0179981.

Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer - PubMed. Available: https://pubmed.ncbi.nlm.nih.gov/29115924/.

Smith CC, Sellitsky SR, Chai S, et al. Alternative tumour-specific antigens. *Nat Rev Cancer* 2019;19:465–78.

Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell* 2015;162:974–86.

Goel S, DeCristo M, Watt AC, et al. Cdk4/6 inhibition triggers anti-tumour immunity. *Nature* 2015;548:471–5.

Smith CC, Beckermann KE, Bortone DS, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. *J Clin Invest* 2018;128:4804–20.

Hurst TP, Magiorakos G. Activation of the innate immune response by endogenous retroviruses. *J Gen Virol* 2015;96:1207–18.

Curty G, Marston JL, de Mulder Rougvie M, et al. Human endogenous retrovirus K in cancer: a potential biomarker and immunotherapeutic target. *Viruses* 2020;12:E726.

Morozov VA, Diao Thi VL, Denner J. The transmembrane protein of the human endogenous retrovirus --K (HERV-K) modulates cytokine release and gene expression. *PLoS One* 2013;8:e70399.

Mangenev Y, Renard M, Schlecht-Louf G, et al. Placental syncytins: genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. *Proc Natl Acad Sci U S A* 2007;104:20534–9.

Blaise S, de Parseval N, Bénit L, et al. Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution. *Proc Natl Acad Sci U S A* 2003;100:13013–8.

Kudo-Saito C, Yura M, Yamamoto R, et al. Induction of immunoregulatory CD271+ cells by metastatic tumor cells that express human endogenous retrovirus H. *Cancer Res* 2014;74:1361–70.

Ficial M, Jegede OA, Sant’Angelo M, et al. Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma. *Clin Cancer Res* 2021;27:1371–80.

Ny L, Jespersen H, Karlsson J, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. *Nat Commun* 2021;12:E726.

Sullivan RJ, Moschos SJ, Johnson M, et al. Abstract CT072: efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy. *Cancer Res* 2019;79:CT072.

Liu M, Thomas SL, Won AY, et al. Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells. *Cancer Res* 2018;78:5754–66.

Griffin GK, Wu J, Iacheta-Vellve A, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. *Nature* 2021;595:203–14.

Vargiu L, Rodriguez-Tomé P, Sperber GO, et al. Classification and characterization of human endogenous retroviruses; mosaic forms are common. *Retrovirology* 2016;13:7.